Cyclooxygenase Polymorphisms and Risk of Cardiovascular Events: The Atherosclerosis Risk in Communities (ARIC) Study
- 9 May 2007
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 83 (1), 52-60
- https://doi.org/10.1038/sj.clpt.6100221
Abstract
Cyclooxygenase-derived prostaglandins modulate cardiovascular disease risk. We genotyped 2212 Atherosclerosis Risk in Communities study participants (1,023 incident coronary heart disease (CHD) cases; 270 incident ischemic stroke cases; 919 non-cases) with available DNA for polymorphisms in PTGS1 and PTGS2. Using a case–cohort design, associations between genotype and CHD or stroke risk were evaluated using proportional hazards regression. In Caucasians, the reduced function PTGS1 −1006A variant allele was significantly more common among stroke cases compared to non-cases (18.2 versus 10.6%, P=0.027). In African Americans, the reduced function PTGS2 −765C variant allele was significantly more common in stroke cases (61.4 versus 49.4%, P=0.032). No significant relationships with CHD risk were observed. However, aspirin utilization appeared to modify the relationship between the PTGS2 G-765C polymorphism and CHD risk (interaction P=0.072). These findings suggest that genetic variation in PTGS1 and PTGS2 may be important risk factors for the development of cardiovascular disease events. Confirmation in independent populations is necessary. Clinical Pharmacology & Therapeutics (2008) 83, 52–60; doi:10.1038/sj.clpt.6100221; published online 9 May 2007Keywords
This publication has 42 references indexed in Scilit:
- Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1)Pharmacogenetics and Genomics, 2007
- NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: The Atherosclerosis Risk in Communities studyPharmacogenetics and Genomics, 2006
- Genetic variation in soluble epoxide hydrolase ( EPHX2 ) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) studyHuman Molecular Genetics, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJCI Insight, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003
- Cyclooxygenase 1(COX1) polymorphisms in African-American and caucasian populationsHuman Mutation, 2002
- Cyclooxygenase-1 and Bicistronic Cyclooxygenase-1/Prostacyclin Synthase Gene Transfer Protect Against Ischemic Cerebral InfarctionCirculation, 2002
- Stroke Incidence and Survival Among Middle-Aged AdultsStroke, 1999
- Neck manipulation as a cause of stroke.Stroke, 1981